Panitumumab Beats Bevacizumab in Left-Sided mCRC

The first trial comparing panitumumab or bevacizumab plus standard chemotherapy has shown that the former significantly improves survival in left-sided Ras wild type metastatic colorectal cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/975064?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?